The use of multiparametric magnetic resonance imaging has allowed for higher accuracy of detecting clinically meaningful cancer, better patient selection, and radiation dose escalation.27,29-31 Staging investigations evolved from the use of conventional imaging to the use of prostate-specific membrane antigen (PSMA)–based positron emission tomography (PET) scans.32 Similar evolution has taken place in post-treatment response assessment. The gene discussed is FOLH1; the disease is cancer.